Page last updated: 2024-11-05

2,6-dichlorophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-dichlorophenol: RN given refers to unlabeled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,6-dichlorophenol : A dichlorophenol with the chloro substituents at positions 2 and 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6899
CHEMBL ID282597
CHEBI ID28457
SCHEMBL ID65234
MeSH IDM0101914

Synonyms (66)

Synonym
CHEBI:28457 ,
2,6-dcp, 2,6-dichlorophenol
2,6-dichlorophenol (2,6-dcp)
2,6-dcp
wln: qr bg fg
2,6-dichlorfenol
nsc60647
nsc-60647
inchi=1/c6h4cl2o/c7-4-2-1-3-5(8)6(4)9/h1-3,9
phenol, 2,6-dichloro-
NCGC00091304-01
rcra waste number u082
brn 1447806
ccris 2511
rcra waste no. u082
einecs 201-761-3
hsdb 4240
nsc 60647
2,6-dichlorfenol [czech]
2,6-dichlorophenol
C07096
87-65-0
2,6-dichlorophenol, 99%
AC-10717
D0394
CHEMBL282597
2,6-dichloro-phenol
BMSE000674
AKOS000120721
A3157
NCGC00091304-02
NCGC00258329-01
dtxcid105004
dtxsid2025004 ,
cas-87-65-0
tox21_200775
2,6-dichlorphenol
bdbm92753
q7e9k52w7e ,
4-06-00-00949 (beilstein handbook reference)
unii-q7e9k52w7e
FT-0610621
2,6-dichlorophenol [hsdb]
dichlorophenol, 2,6-
lofexidine metabolite (2,6 dcp)
2,6-dichlorophenol [mi]
STL264123
SCHEMBL65234
2.6-dichlorophenol
2,6 dichlorophenol
W-104010
STR01713
mfcd00002176
2,6-dichlorophenol, pestanal(r), analytical standard
2,6-dichlorophenol, 98%
2,6-dichlorophenol; nsc 60647; phloroglucinol impurity i
2,6-dichlorophenol 100 microg/ml in methanol
2,6-dichlorophenol 10 microg/ml in methanol
CS-D1414
DUB ,
Q4596801
EN300-21048
AMY8679
25511-62-0
Z104486756
2,6-dichlorophenol 1000 microg/ml in methanol

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Consequently, the toxic activity of the test compounds was controlled by electrophilic index and electronic properties."( Dechlorination of chlorinated compounds by Trametes versicolor ATCC 200801 crude laccase and quantitative structure-activity relationship of toxicity.
Aytar, P; Çabuk, A; Gedikli, S; Sidir, İ; Sidir, YG, 2012
)
0.38

Bioavailability

ExcerptReferenceRelevance
" To search for potent and orally bioavailable STAT6 inhibitors, we synthesized a series of 4-benzylaminopyrimidine-5-carboxamide derivatives and evaluated their STAT6 inhibitory activities."( Identification of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide derivatives as potent and orally bioavailable STAT6 inhibitors.
Iwata, M; Koakutsu, A; Kuromitsu, S; Moritomo, H; Nagashima, S; Nagata, H; Ohga, K; Ohta, M; Orita, M; Takeuchi, M; Tsukamoto, S; Yokota, M, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Surprisingly, 2,6-DCP has certain biodegradability and could be used as an environmentally friendly metabolic uncoupler under low-concentration dosing conditions."( Insight investigation of the on-site activated sludge reduction induced by metabolic uncoupler: Effects of 2,6-dichlorophenol on soluble microbial products, microbial activity, and environmental impact.
Li, L; Lin, Q; Tian, Y; Yin, L; Zhang, J; Zuo, W, 2022
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dichlorophenolAny chlorophenol carrying chloro substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.02380.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency31.64330.000221.22318,912.5098AID743035; AID743042; AID743063
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.98470.003041.611522,387.1992AID1159553
farnesoid X nuclear receptorHomo sapiens (human)Potency35.48130.375827.485161.6524AID588527
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency29.98470.001723.839378.1014AID743083
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency33.49150.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Pentachlorophenol 4-monooxygenaseSphingobium chlorophenolicumKd45.50000.05003.75007.0000AID1799831
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID343070Dissociation constant, pKa of the compound2008Bioorganic & medicinal chemistry, Jul-01, Volume: 16, Issue:13
Identification of 4-benzylamino-2-[(4-morpholin-4-ylphenyl)amino]pyrimidine-5-carboxamide derivatives as potent and orally bioavailable STAT6 inhibitors.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID24227Partition coefficient (logP)1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.
AID1799833Inhibition Assay from Article 10.1021/bi200855m: \\Substrate specificity of Sphingobium chlorophenolicum 2,6-dichlorohydroquinone 1,2-dioxygenase.\\2011Biochemistry, Oct-18, Volume: 50, Issue:41
Substrate specificity of Sphingobium chlorophenolicum 2,6-dichlorohydroquinone 1,2-dioxygenase.
AID1799831Spectroscopic Assay from Article 10.1021/bi300261p: \\Pentachlorophenol hydroxylase, a poorly functioning enzyme required for degradation of pentachlorophenol by Sphingobium chlorophenolicum.\\2012Biochemistry, May-08, Volume: 51, Issue:18
Pentachlorophenol hydroxylase, a poorly functioning enzyme required for degradation of pentachlorophenol by Sphingobium chlorophenolicum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (18.37)18.7374
1990's5 (10.20)18.2507
2000's21 (42.86)29.6817
2010's12 (24.49)24.3611
2020's2 (4.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.85 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index63.28 (26.88)
Search Engine Supply Index1.98 (0.95)

This Compound (43.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]